Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B)

BACKGROUND: To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal cell carcinoma (nccRCC) and the efficacy of nivolumab/ipilimumab salvage therapy in patients with tumors unresponsive to initial nivolumab monotherapy. METHODS: Eligible...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkins, Michael B, Jegede, Opeyemi A, Haas, Naomi B, McDermott, David F, Bilen, Mehmet A, Stein, Mark, Sosman, Jeffrey A, Alter, Robert, Plimack, Elizabeth R, Ornstein, Moshe C, Hurwitz, Michael, Peace, David J, Signoretti, Sabina, Denize, Thomas, Cimadamore, Alessia, Wu, Catherine J, Braun, David, Einstein, David, Catalano, Paul J, Hammers, Hans
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040058/
https://www.ncbi.nlm.nih.gov/pubmed/36948504
http://dx.doi.org/10.1136/jitc-2022-004780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040058/
https://www.ncbi.nlm.nih.gov/pubmed/36948504
http://dx.doi.org/10.1136/jitc-2022-004780

Ejemplares similares